Cargando…

Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells

Use of epidermal growth factor receptor (EGFR) inhibitors represented by gefitinib and erlotinib has become the standard of treatment for non-small-cell lung cancers (NSCLCs) with activating EGFR mutations. However, the majority of NSCLCs, which overexpress EGFR without such mutations, are resistant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Shuhei, Okada, Masashi, Takeda, Hiroyuki, Kuramoto, Kenta, Sanomachi, Tomomi, Togashi, Keita, Seino, Shizuka, Yamamoto, Masahiro, Yoshioka, Takashi, Kitanaka, Chifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135698/ https://www.ncbi.nlm.nih.gov/pubmed/30220973 http://dx.doi.org/10.18632/oncotarget.25994

Ejemplares similares

Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson’s disease, as an anti-cancer stem cell drug
por: Okada, Masashi, et al.
Publicado: (2017)

Inhibition of the Lipid Droplet–Peroxisome Proliferator-Activated Receptor α Axis Suppresses Cancer Stem Cell Properties
por: Kuramoto, Kenta, et al.
Publicado: (2021)

Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing
por: Suzuki, Shuhei, et al.
Publicado: (2020)

Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
por: Sanomachi, Tomomi, et al.
Publicado: (2019)

Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction
por: Suzuki, Shuhei, et al.
Publicado: (2021)

Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction
por: Suzuki, Shuhei, et al.
Publicado: (2019)

Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1–JNK axis
por: Suzuki, Shuhei, et al.
Publicado: (2021)

In vitro and in vivo anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile
por: Suzuki, Shuhei, et al.
Publicado: (2019)

Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells
por: Shibuya, Keita, et al.
Publicado: (2014)

Licochalcone A specifically induces cell death in glioma stem cells via mitochondrial dysfunction
por: Kuramoto, Kenta, et al.
Publicado: (2017)

Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo
por: Takeda, Hiroyuki, et al.
Publicado: (2017)

The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo
por: Okada, Masashi, et al.
Publicado: (2016)

JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells
por: Suzuki, Shuhei, et al.
Publicado: (2014)

Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma Xenografts
por: Okada, Masashi, et al.
Publicado: (2021)

Targeting the K-Ras - JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation
por: Okada, Masashi, et al.
Publicado: (2014)

Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins
por: Yamamoto, Masahiro, et al.
Publicado: (2022)

Inhibition of the Phospholipase Cε–c-Jun N-Terminal Kinase Axis Suppresses Glioma Stem Cell Properties
por: Okada, Masashi, et al.
Publicado: (2022)

Domatinostat Targets the FOXM1–Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents
por: Nakagawa-Saito, Yurika, et al.
Publicado: (2023)

HDAC Class I Inhibitor Domatinostat Preferentially Targets Glioma Stem Cells over Their Differentiated Progeny
por: Nakagawa-Saito, Yurika, et al.
Publicado: (2022)

Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells
por: Mitobe, Yuta, et al.
Publicado: (2023)

Targeting JNK for therapeutic depletion of stem-like glioblastoma cells
por: Matsuda, Ken-ichiro, et al.
Publicado: (2012)

The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo
por: Mitobe, Yuta, et al.
Publicado: (2023)

ET-6 Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Involvement of GLUT1 and GLUT3 in the growth of canine melanoma cells
por: Suwabe, Yoko, et al.
Publicado: (2021)

Expression of the glucose transporters GLUT1, GLUT3, GLUT4 and GLUT12 in human cancer cells
por: Barron, Carly, et al.
Publicado: (2012)

ET-7 Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Sweat glucose and GLUT2 expression in atopic dermatitis: Implication for clinical manifestation and treatment
por: Ono, Emi, et al.
Publicado: (2018)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

Functional Analyse of GLUT1 and GLUT12 in Glucose Uptake in Goat Mammary Gland Epithelial Cells
por: Yu, Qinghua, et al.
Publicado: (2013)

BAG6 contributes to glucose uptake by supporting the cell surface translocation of the glucose transporter GLUT4
por: Minami, Setsuya, et al.
Publicado: (2020)

A role for GLUT3 in glioblastoma cell invasion that is not recapitulated by GLUT1
por: Libby, Catherine J, et al.
Publicado: (2021)

Glucose transporters GLUT1, GLUT3, and GLUT4 have different effects on osteoblast proliferation and metabolism
por: Arponen, Milja, et al.
Publicado: (2022)

Placental expression of glucose transporters GLUT‐1, GLUT‐3, GLUT‐8 and GLUT‐12 in pregnancies complicated by gestational and type 1 diabetes mellitus
por: Stanirowski, Paweł Jan, et al.
Publicado: (2021)

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2012)

GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle
por: Aerni-Flessner, Lauren, et al.
Publicado: (2012)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Glut1 and Glut3 as Potential Prognostic Markers for Oral Squamous Cell Carcinoma
por: Ayala, Fernanda Rocha Rojas, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_s9hio05tkg979ta1ut6t5q3bho